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ABSTRACT 
 
THOMAS HIGGINS: Molecular Characterization of β2 Adrenergic Receptor Haplotypes 
(Under the direction of Dr. Luda Diatchenko) 
 
 
Adrenergic receptor β2 (ADRB2) is a primary target for epinephrine. It is critical in 
mediating physiological responses to environmental stressors and affects a complex array 
of psychological and physiological characteristics: including asthma, hypertension, and pain 
sensitivity. We searched the ADRB2 promoter region for transcriptional activator putative 
binding sites, which revealed CREB, p65, and C/EBP binding sites. We constructed a 
luciferase reporter vector containing three major polymorphic variant haplotypes of a 2.0 kb 
human ADRB2 promoter region, and transiently transected the constructs into liver, 
neuronal, and immune cell lines. We demonstrated; a) different levels of basal promoter 
activity related to three major human haplotypes; b) tissue specific regulation of ADRB2 
promoter at the basal level and upon treatment; c) haplotypes exhibited similar response 
patterns, demonstrating haplotype-independent transcription regulation by C/EBP, NFκB, 
and cAMP. These results are the first to demonstrate haplotype-dependent regulation of 
ADRB2 by cAMP, NFκB, and C/EBP pathways. 
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CHAPTER 1 
BACKGROUND & SIGNIFICANCE 
 
Adrenergic receptor β2 (ADRB2) is a membrane-bound G-protein coupled receptor. It is 
expressed throughout the body and participates in intracellular signaling. It is the primary 
signaling receptor of the Sympathetic Nervous System and is responsible for maintaining 
homeostasis in the body. ADRB2 plays a role in several disease states, including: 
hypertension, asthma, and chronic pain conditions1-19. To get at the pathophysiology, 
genetic analyses of the ADRB2 gene locus have revealed a number of common 
polymorphic variants. However, a comprehensive analysis of how these variants affect 
receptor expression have not been done and the exact pathophysiology underlying receptor 
expression and dysfunction are not well characterized.  
 
Protein Structure and Functional Properties of ADRB2.  
ADRB2 is a low abundance membrane-integrated protein that mediates the effects of 
cell-surface catecholamines. Epinephrine is the primary ligand and signaling molecule in the 
periphery (highest affinity), whereas norepinephrine is the primary signaling molecule in the 
sympathetic nervous system. ADRB2 is composed of a single polypeptide chain consisting 
of 413 amino acid residues with a molecular weight of 46,557 Daltons for the unmodified 
precursor. The receptor undergoes three types of post-translational modification that can 
alter protein structure and molecular weight: glycosylation, palmitoylation, and disulfide bond 
formation. N-linked glycosylation is the addition of N-linked sugars to the protein at amino 
acids 6, 15, and 187. Glycosylation is responsible for membrane insertion and agonist-
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induced receptor trafficking20-22. Palmitoylation occurs at the cysteine residue of amino acid 
341, and is responsible for reversible anchoring of the carboxy-terminus to the membrane23. 
Palmitoylation has been found to stimulate agonist-induced adenylyl cyclase activity and 
affects ADRB2 phosphorylation and desensitization24-27. Disulfide bonds formation has been 
found to occur at cysteine residues 106, 184, 190, and 191. These bonds function to 
stabilize the ADRB2 ligand-binding pocket28-31. 
ADRB2 is a member of the large superfamily of G-protein-coupled receptors (GPCRs). 
GPCRs signal through intracellular association with membrane-associated GTP-binding 
proteins (G-proteins). The term ‘G-proteins’ is usually used to refer to heterotrimeric G-
proteins, which consist of the associated subunits Gα, Gβ, and Gγ. Gα subunits consist of a 
GTPase and an alpha-helical domain. The Gβ and Gγ subunits are tightly bound and form 
the beta-gamma complex (Gβγ complex). 
Like all GPCRs, ADRB2 is a protein that has seven alpha-helical hydrophobic 
transmembrane-spanning domains, an extracellular amino terminus, an intracellular 
carboxyl terminus, three interconnecting extracellular loops, and three intracellular loops32,33 
(see Fig. 1). Agonist binding occurs in the extracellular pockets between the third to fourth 
and fifth to sixth transmembrane domains.  
 
Intracellular Signaling 
As a GPCR, ADRB2 is involved in intracellular signaling through association with 
heterotrimeric G-proteins. The stimulatory heterotrimeric G-protein, Gs, is the primary 
signaling complex associated with ADRB2. Agonist binding to ADRB2 temporarily stabilizes 
the receptor in the activated conformational state, which allows the Gαs G-protein subunit to 
couple to the second and third intracellular loops and cytoplasmic tail. Gs consensus binding 
sequences have not been identified; therefore, tertiary structure is thought to be critical for 
Gs binding to ADRB2. Association of the G-protein with the activated receptor causes Gαs to 
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release bound GDP, which allows binding of GTP (guanosine 5'-triphosphate). GTP 
catalyzes dissociation of the G-protein heterotrimer into activated Gαs and Gβγ subunits. 
Gαs couples with and activates adenylyl cyclase (AC), which catalyzes the conversion of 
ATP into cAMP (cyclic AMP or adenosine 3',5'-cyclic monophosphate) and increases cAMP 
levels34. cAMP then catalyzes the activation of protein kinase A (PKA). Activated PKA 
catalytic subunits can phosphorylate proteins and activate downstream signaling cascades. 
One pathway functions to activate gene transcription. This occurs when PKA translocates to 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. ADRB2 protein composition and structure32. 
 
Reprinted from J Allergy Clin Immunol, 110, Liggett, S. B., Update on current 
concepts of the molecular basis of beta2-adrenergic receptor signaling, S223-7, 
 
Copyright© (2002), with permission from Elsevier. 
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Figure 2. ADRB2 signaling pathway. The classic ADRB2 G-protein signaling 
pathway occurs through association of the receptor with Gαs. Upon binding of the 
ADRB2 agonist epinephrine (Epi), Gαs exchanges its GDP for GTP and dissociates 
into activated Gαs and Gβγ complexes. Activated Gαs binds to and activates the 
enzyme adenylyl cyclase (AC). AC rapidly catalyzes the formation of cAMP from ATP 
through removal of a pyrophosphate. Several cAMP molecules bind to and activate 
protein kinase A (PKA). (1) The catalytic PKA subunits translocate to the nucleus 
where it phosphorylates CREB, which allows binding of CREB with CREB-binding 
protein (CBP). CREB then binds to the CRE promoter and activates gene 
transcription. (2) PKA phosphorylates the intracellular C-term of the ADRB2, and (3) 
other intracellular signaling molecules. 
 
 
the nucleus where it phosphorylates cAMP response element-binding protein (CREB) (Fig. 
2, part 1). CREB then binds CREB-binding protein (CBP) and binds to a cAMP response 
element (CRE) domain in the promoter region of a target gene, which initiates transcription. 
In addition, PKA functions in a negative feedback loop by phosphorylating the receptor, 
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which leads to uncoupling of Gs and decreased signal transduction. Gβ and Gγ subunit 
composition has been found to alter specificity of ADRB2 Gs activation
35 and adenylyl 
cyclase signaling36,37. The Gβγ subunit can also participate in downstream signaling 
cascades. These occur via several mechanisms and have effects on cell proliferation, 
survival, endocytosis, IP3 signaling, and PKA signaling38.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3. ADRB2 desensitization by uncoupling, β-arrestin binding, and 
internalization. (1) PKA participates in a negative feedback loop whereby 
phosphorylated serine residues on the C-term cause Gαs uncoupling, which leads to 
decreased Gαs signaling and functional desensitization. (2) PKA can also 
phosphorylate GRK2, which phosphorylates serine/threonine residues on the C-term. 
Phosphorylated residues permit binding of β-arrestin, which inhibits signaling. (3) 
Finally, β-arrestin can lead to internalization of the receptor. This occurs through 
association of AP-2 and clathrin with β-arrestin. The plasma membrane folds in and 
forms and endosome that carries the receptor into the cytosol. 
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Desensitization 
When GPCRs are continuously activated in the presence of agonist, they can undergo 
desensitization. Desensitization is the decrease in sensitivity to agonist-stimulated receptor 
functioning. Desensitization occurs by three main mechanisms: (a) phosphorylation, (b) 
internalization, and (c) down-regulation. Phosphorylation is the process whereby a 
phosphate group is added to amino acid residues on the intracellular region of the protein, 
which leads to an uncoupling of the G-protein Gαs and inhibition of downstream signaling 
(Fig. 3, part 1). This can occur directly by PKA at serine residues, on the third intracellular 
loop and the carboxyl terminus (Fig. 2, part 2).  
In addition, PKA can phosphorylate GPCR kinases (GRKs). The most common GRK 
associated with ADRB2 is the beta adrenergic receptor kinase 1 (ADRBK1), more commonly 
known as GRK2. GRK2 then phosphorylates serine and threonine residues on the carboxyl 
terminus of ADRB2, which promotes binding of the scaffolding protein β-arrestin to the 
cytoplasmic tail. Binding of β-arrestin leads to uncoupling of the Gαs subunit from ADRB2 
and inhibition of downstream signaling (Fig. 3, part 2)39,40. Both mechanisms can lead to 
altered receptor conformation and decreased ability to bind agonist and activate signaling 
cascades. Binding of β-arrestin initiates uncoupling and prevents association of the receptor 
with G-proteins, which inhibits signaling41,42. Gβγ can act as a membrane anchor for GRK2, 
enhance its activation, and facilitate desensitization and internalization43,44. 
Another mechanism responsible for desensitization of ADRB2 is PKA-dependent Gs to 
Gi switching (Fig. 4). Switching occurs following phosphorylation of the receptor by PKA and 
uncoupling of Gs. Decreased Gs coupling leads to increased Gi, which leads to feedback 
inhibition of Gs signaling through inhibition of adenylyl cyclase and desensitization of the 
receptor (Fig. 4, part 1). In addition, Gi coupling leads to activation of the MAPK signaling 
pathway through Src, Sos, and Ras signaling (Fig. 4, part 2). The net effect of Gs to Gi 
switching is desensitization of traditional Gs ADRB2 signaling, and activation of an alternate 
7 
Adenylyl
Cyclase
β γ
Erk1/2
Src
ADRB2
Epi
GDP
Gi
α
GTP
Gi
αGDP
Gs
α
x
1) AC inhibition
2) ERK1/2 pathway
signaling pathway responsible for specificity of signaling45,46. Finally, Gs and Gi dual coupling 
has been observed in cardiac myocytes, which is responsible for chronotropic control47. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4. Gs to Gi switching. G-protein switching occurs when Gαs is uncoupled 
from ADRB2 and Gαi associates with the receptor. Gαi becomes activated through 
exchange of GDP for GTP, and can participate in desensitization by preventing Gαs 
from binding to ADRB2. (1) Desensitization also occurs by preventing activation of 
adenylyl cyclase and PKA-dependent signaling. In addition Gαi can activate a MAP 
Kinase signaling pathway through c-Src, which signals through SOS, Ras, c-Raf, and 
ERK1/2 to participate in gene expression.  
 
 
 
 
Receptor internalization (or sequestration) (Fig. 3, part 3) is the process of agonist-
induced receptor desensitization by which the plasma membrane folds inward to form a 
clathrin-coated vesicle32. The vesicle enters the cell as an endosome and receptors are not 
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available for signaling. This process occurs when clathrin and AP-2 associate with ADRB2-
bound β-arrestin and initiates formation of clathrin-coated pits48,49. Receptors are targeted to 
endosomes where they remain intact, and can be rapidly recycled back to the membrane to 
produce resensitization of receptor signaling. This process begins when phosphatases 
dephosphorylate the internalized receptors. The endosome is targeted for the plasma 
membrane where it fuses and rapidly increases the number of surface receptors. This 
resensitization leads to dynamic restoration of signaling following agonist-induced 
desensitization.  
Down-regulation occurs during prolonged agonist activation, and is a decrease in the 
number of cell surface-expressed receptors. Down-regulation typically requires several 
hours or longer of agonist exposure (as opposed to minutes for phosphorylation and 
internalization), and the mechanisms leading to the process are highly cell-type dependent. 
These mechanisms include a decrease in gene transcription, destabilization of mRNA, and 
degradation of receptor protein32. Degradation of receptor protein begins with internalization 
of the receptor. However, instead of being recycled to the membrane receptors are targeted 
to lysosomes for degradation by proteases. This leads to a long-term decrease in the 
number of receptors and decreased signaling. 
 
ADRB2 Genomic Structure and Polymorphisms.  
Human ADRB2 (NCBI GeneID: 154) is an intronless gene that spans approximately 
5,500 bp on chromosome 5q31-32. Its full-length mRNA spans 2,033 bp and includes the 5'- 
and 3'-untranslated region (UTR) (NCBI NM_000024). The protein coding region spans 
1,239 bp within the full-length mRNA.  
 
Flanking Regions 
The flanking sequences of ADRB2 are highly conserved among humans, rabbit, mouse, 
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and hamster50. The functional significance of these regions is supported by the presence of 
multiple potential cis-acting regulatory elements (transcription factor binding sites) in the 
promoter50-57 and glucocorticoid-response elements in the 3' flanking region50. ADRB2 
mRNA is of low abundance but commonly expressed in various human tissues50. 
Polymorphisms in the promoter region can affect transcription efficiency by altering the 
ability of the transcriptional machinery to bind to the gene and initiate transcription. 
Regulatory activity has been identified in the 550bp promoter region, where at least five 
common SNPs have been identified that may be responsible for regulation of transcription 
efficiency53,54. This regulation can occur by altering transcription factor binding domains or 
regions adjacent to these domains. SNPs in the promoter region have been found to 
decrease the rate of transcription51,52.  
 
Protein Coding Region 
 There are a number of reported single nucleotide polymorphisms (SNPs) within the 
ADRB2 gene locus. The NCBI ADRB2 locus database shows SNPs 33 identified in the 
transcribed region of the ADRB2 that span over 2 kb. In the coding region of the human 
ADRB2, twelve polymorphisms have been identified, five of which are 
nonsynonymous33,51,58,59. Nonsynonymous polymorphisms are those that lead to an amino 
acid change, whereas synonymous polymorphisms code for the same amino acid. The 
nonsynonymous polymorphisms occur in the amino terminus of the receptor at positions 46 
(Arg16Gly) and 79 (Gln27Glu), the first transmembrane spanning domain at position 100 
(Val34Met), the fourth transmembrane spanning domain at position 491 (Thr164Ile), and the 
fifth transmembrane spanning domain at position 659 (Ser220Cys). Three of the 
nonsynonymous polymorphisms have been found to alter ADRB2 function: 16, 27, and 164. 
The Gly16 receptor undergoes enhanced agonist-promoted down-regulation of receptor 
number in comparison to the Arg16 receptor60,61. In contrast, the Glu27 receptor undergoes 
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very little agonist-promoted down-regulation compared to the Gln27 receptor60,61; however, 
the functional effect is reversed—the Glu27 allele is associated with increased 
desensitization of cell stiffness and cAMP accumulation62. These variants are common in 
human populations; whereas the Ile164 receptor only occurs in the heterozygous state in 
approximately 5% of the population. The Ile164 allele displays decreased Gs coupling
63, as a 
result Ile164 allele is associated with decreased adenylyl cyclase activation and signaling, 
while clinically it leads to lower heart rate and cardiac contractibility63. These data are 
complicated by the fact that SNPs are conferred in evolutionarily conserved units called 
haplotypes. Individual SNPs do not accurately predict the phenotype because they are 
found in haplotypes with other SNPs. 
 
Haplotype 
A haplotype is simply a set of SNPs that are statistically linked; however, more 
commonly a haplotype is understood as a set of alleles at multiple linked loci that are 
conferred genetically. Haplotypes in the human genome form haplotype blocks (or 
‘haploblocks’), which are blocks of associated SNPs that are highly associated (in linkage 
disequilibrium). The SNPs in haploblocks are so well associated that identification of a 
single SNP can be used to predict the genotype of other SNPs within the haploblock 64.  
Genetic analysis of ADRB2 has revealed that there is only one haploblock for the gene 
locus and that this haploblock has been well-characterized65. Therefore, we were able to 
perform a haplotype reconstruction using only a few common SNPs. Since SNPs are always 
conferred together in haploblocks that comprise haplotypes, haplotype is a better predictor 
of phenotype than individual SNPs. Several studies have reported three major ADRB2 
haplotypes, which represent approximately 99% of the sample participants used in the 
studies51,65,66. Haplotype effects on ADRB2 desensitization have been reported67. ADRB2 
mRNA levels and receptor density, in HEK293 cells transfected with the haplotype 
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associated with a greater physiological response (measured by forced expiratory volume) 
(‘haplotype 1’ in the paper from our group, Diatchenko et al. (2006)66), were approximately 
50% greater than those transfected with the lower response haplotype (‘haplotype 2’ in the 
paper from our group, Diatchenko et al. (2006))51. These findings were the first to indicate 
that unique interactions among multiple SNPs within a haplotype can affect biologic and 
therapeutic phenotypes and that individual SNPs may have poorer predictive power 
compared to haplotypes. Thus, the ADRB2 gene is highly polymorphic with nonsynonymous 
SNPs resulting in receptors that have distinct characteristics regarding ligand binding, 
functional coupling, and agonist-promoted regulation.  
Our group has demonstrated phenotypic effects of ADRB2 haplotype. Individuals 
heterozygous for one high and one low expressing haplotype had the highest positive 
psychological traits, higher resting blood pressure, and were ten times less likely to develop 
an idiopathic pain disorder66.  
 
Association of ADRB2 with Disease States. 
 
Role in Sympathetic Nervous System 
The Autonomic Nervous System (ANS) is responsible for maintaining homeostatic 
balance in the body through a set of complimentary or ‘opposing’ functions. These functions 
are controlled by adrenergic receptors in the sympathetic branch of the ANS, and 
muscarinic receptors in the parasympathetic branch. Adrenergic receptors in the 
Sympathetic branch that bind catecholamines are responsible for preparing the body to 
respond to environmental challenges that require fast action and mobilization of critical 
energy resources (the ‘fight or flight’ response). This leads to decreased blood flow to the GI 
tract, increased blood flow to skeletal muscles, dilation of bronchioles of the lung, and 
increased heart rate and contractility of cardiac tissue. However, the different subtypes of 
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adrenergic receptors react differently to catecholamines and are expressed at different 
levels throughout the body. ADRB2 responds to catecholamine release (primarily 
epinephrine) by increasing heart rate along with β1-adrenergic receptors (ADRB1) on 
cardiac tissue. ADRB2 is responsible for vascular smooth muscle relaxation acutely, 
whereas α1-adrenergic receptors (ADRA1) lead to contraction. However, ADRA1 is more 
highly expressed and contributes more to the prolonged sympathetic response in vascular 
smooth muscles than ADRB2. ADRB2 is highly expressed on and responsible for bronchiole 
smooth muscle relaxation; whereas, ADRA1 is less abundant and contraction has only a 
minor effect on bronchiole smooth muscle response. ADRB2 knockout mice show a mostly 
normal phenotype, with the exceptions of altered vascular functioning and energy 
metabolism68. They show a decreased hypotensive response to ADRB2 agonist, become 
hypertensive during exercise, have decreased respiratory exchange during exercise, and 
show an exaggerated response to epinephrine. These effects of ADRB2 absence highlight 
the importance of ADRB2 to the sympathetic nervous system in maintaining homeostatic 
control, particularly during times of stress. However, the relatively normal phenotype at rest 
suggests that overlapping and/or compensatory mechanisms are adequate to maintain 
normal functioning in the absence of a challenge. 
Disease states can occur when sympathetic response is altered. Acute release of 
catecholamines is useful for mobilizing energy resources in preparation to react to external 
stimuli. However, prolonged stress or anxiety can lead to chronically high levels of 
catecholamines and chronic activation of the sympathetic system. Another possible 
alteration can occur when altered levels of adrenergic receptors are expressed in tissues 
leading to altered responses to sympathetic activation. 
 
Hypertension 
Hypertension is a serious medical condition that is associated with increased risk for 
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stroke, coronary heart disease, and vascular disease. An estimated 16-25% of adults suffer 
from elevated blood pressure and an estimated 23,000 deaths are attributed to the disease 
each year69,70. Even a modest decrease of blood pressure of 5-6 mmHg can reduce stroke 
risk by 40% and coronary heath disease by 15-20%.  
In the presence of epinephrine, ADRB2 localized in cardiac tissue leads to increased 
heart rate and force of contraction. In contrast, ADRB2 on vascular smooth muscle tissue 
leads to vasodilation and an initial drop in blood pressure at low concentrations of 
epinephrine; however, this effect is eclipsed by vascular smooth muscle constriction that 
follows ADRA1 activation by higher concentrations of epinephrine71. This allows increased 
blood flow to vital organs, but decreased blood flow to peripheral organs not essential for 
energy mobilization, which has a net effect of increasing blood pressure. This suggests that 
ADRB2 does not contribute significantly to the underlying development and clinical 
manifestation of hypertension.  
Clinical and genetic evidence suggests a modulatory role for ADRB2 in hypertension, 
rather than a causative role. ADRB2 is highly expressed in the kidney72,73, where it causes 
release of renin in response to epinephrine74-79. Renin activates the renin-angiotensin-
aldosterone system, which increases sympathetic activity, salt re-absorption, water 
retention, and thus a increase in blood pressure80,81. Therefore, increased expression or 
activity of ADRB2 in the kidneys can lead to hypertension. Genetic evidence demonstrates 
the role of an ADRB2 diplotype in regulating renin and aldosterone, which leads to a type of 
salt-sensitive hypertension82. An ADRB2 polymorphism has been shown to alter ADRB2 
responsiveness to Na+ in the kidneys 83 and alter cardiovascular function84, which both can 
lead to hypertension. 
ADRB2 receptor variants have been associated with risk and development of 
hypertension81,85-90. ADRB2 variants have been associated with differences in resting blood 
pressure91, cardiac function92, vascular activity82, and cardiovascular stress reactivity89. 
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These data can be explained by the overlapping roles of ADRB1 and ADRB2 in the 
sympathetic nervous system and control of blood pressure. In addition, altered levels of 
ADRB2 in relation to ADRB1 could provide a compensatory mechanism that makes ADRB2 
more critical in the genesis or modulation of hypertension in individuals with specific SNPs 
or haplotypes. In addition, genetic predisposition to blood pressure modulation may be 
altered by environmental factors. 
A number of environmental factors are thought to play a role in disease etiology, such as 
excessive salt intake, obesity, alcohol, and stress. However, the disease is a common 
complex genetic disorder (polygenic) with high genetic heritability (30%). Therefore, 
elucidation of the effects of genetic polymorphic variants on receptor expression and 
functioning in cardiac and vascular tissues could lead to improved clinical diagnosis, 
treatment, and outcomes for hypertension and its associated diseases.  
 
Asthma 
Asthma is a chronic inflammatory disease of the respiratory tract, whereby the bronchial 
tissues constrict, become inflamed, and secrete mucous. Repeated exposure to 
environmental triggers can cause sensitization of the bronchial tissue, increased 
inflammation, and airway obstructions during an acute asthma ‘attack.’ A number of 
environmental factors contribute to the etiology of the disease, such as poor air quality and 
exposure to airborne allergens. An estimated 14 million adults and 4 million children in the 
U.S. are currently living with asthma, which represents 5% of the population93,94. Disease 
prevalence increased by 74% from 1980-199695. This rapid increase in prevalence highlights 
the need for further advances in understanding of disease etiology, improved clinical 
diagnosis, and treatment. 
ADRB2 is an important therapeutic target for acute asthma attacks9,10; specific ADRB2 
agonists cause relaxation of bronchiole smooth muscles, and ADRB2 polymorphisms have 
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been shown to modulate responses to asthma treatment96-107. ADRB2 polymorphisms impart 
a predisposition to nocturnal asthma and moderately increase asthma severity102. This 
process is mediated by G-protein-dependent adenylyl cyclase stimulation and subsequent 
cAMP formation. cAMP activates PKA, which phosphorylates multiple proteins, leading to 
smooth muscle relaxation, and bronchodilation (Fig. 2, part 3)32,108,109. Despite its role in 
treating asthma, ADRB2 is not a major contributing factor in disease onset or 
severity96,97,102,103,110. Effects have been observed for altered receptor expression and 
responsiveness in asthmatics11, but this may affect treatment rather than pathophysiology. 
Haplotype effects have been observed for response to ADRB2 agonists in asthma 
treatment60,98,111-113. One of these effects is due to a decrease in ADRB2 agonist-induced 
down-regulation, which was associated with increased bronchodilator response112-114. 
Haplotypes associated with decreases in mRNA and protein level have been associated 
with decreased bronchodilator response to agonist51. Haplotype effects have been observed 
for tolerance to agonist-mediated bronchodilation and bronchoprotection111,115,116.  
Although ADRB2 is not responsible for the pathophysiology of asthma, it does play a 
significant role in treatment. This is due to the bronchodilatory effect of ADRB2 on bronchial 
smooth muscle, which is primarily a function of the sympathetic nervous system—to prepare 
the body for action by increasing air flow5-8. Asthma treatment takes advantage of this 
coincidental ADRB2 expression to induce bronchodilation in asthmatics. Although ADRB2 
does not appear to be significant to the pathophysiology of asthma, its association with 
asthma may be due to the overlapping and complimentary role it plays in alleviation of 
asthma. Therefore, elucidation of the effects of genetic polymorphic variants and haplotype 
on receptor expression and functioning in respiratory and bronchial tissues could lead to 
improved choice of therapeutic interventions for asthma sufferers.  
 
Chronic Pain 
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Chronic pain is any pain that persists in the absence of normal pain-evoking stimuli. The 
pain can be intermittent or constant, and often does not have a clear cause. One of the main 
symptoms is hyperalgesia, heightened sensitivity to painful stimuli. However, sometimes 
sufferers experience allodynia, which is the sensation of pain to a normally non-painful 
stimulus. This heightened sensitivity to pain can impair an individual’s daily functioning by 
preventing activity, overwhelming the senses, or pervading thought and awareness. Chronic 
pain conditions are thought to affect as much as 25% of the US population at some point in 
their lives117-119. There is a clear psychological and physiological component120 and there is 
evidence that genetic polymorphisms mediate pain sensitivity and risk for developing 
chronic pain conditions66,121,122. Clinically, the non-specific beta-blocker propranolol has been 
successfully used for treatment of migraine123-128 fibromyalgia129, and rheumatoid 
arthritis15,130. Ultimately, development and maintenance of a chronic pain condition is 
influenced my many environmental, psychosocial, and genetic factors—making study of 
these conditions challenging. 
Pain perception is strongly influenced by adrenergic receptors of the Sympathetic 
Nervous System. Elevated levels of catecholamines, such as epinephrine, promotes the 
production of persistent pain states via the stimulation of β-adrenergic receptors in the 
periphery and central nervous system. In both experimental animals models of and in 
humans with rheumatoid arthritis, sympathectomy or the administration of a β-receptor 
antagonist (propranolol) delays the onset and reduces the severity of arthritis and joint 
responses to injury13,14,130-133. In addition systemic β-adrenergic receptor blockade, either 
before or after the onset of disease expression, attenuates clinical manifestations in animal 
models of arthritis130; and the systemic administration of propranolol produces symptomatic 
improvement of rheumatoid arthritis in humans15. Sustained (7 to 14 days) bioavailability of 
epinephrine released from either the adrenal medulla or administered exogenously 
substantially augments inflammatory mediator-induced hyperalgesia by producing a time-
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dependent desensitization of ADRB245. It has also been shown that patients with a localized 
muscle pain condition show diminished ADRB2-mediated vasodilatation in response to a 
physical stressor, and that subgroups of fibromyalgia patients show diminished vasodilatory 
responses to stressors. There is further biochemical evidence that ADRB2s are desensitized 
or down regulated in fibromyalgia patients because G-protein dependent adenylyl cyclase 
responses to ADRB2 stimulation are impaired in these patients134. There is evidence that 
myogenous temporomandibular joint disorder (TMJD) is associated with a sustained 
elevation in catecholamines. Patients with painful TMJD-like conditions have higher urinary 
catecholamine and augmented sympathetic responses to stressors18,135. Our group reported 
findings in Diatchenko et al. 2006 that individuals who carried one haplotype coding for high 
expression and one coding for low expression were approximately ten times less likely to 
develop the chronic musculoskeletal pain condition, temporomandibular joint disorder 
(TMJD)66. In addition, our group found that inhibition of catechol-O-methyl transferase 
(COMT) activity enhanced pain sensitivity in rats through activation of ADRB2 and 
ADRB3136.  
Genetic analysis of ADRB2 has shown that ADRB2 is associated with opioid-induced 
hyperalgesia in a haplotype-specific and mouse strain-specific manner137,138. ADRB2 SNPs 
have been associated with rheumatoid arthritis139, risk for development of a chronic 
musculoskeletal pain condition66, and vasospastic angina140. ADRB2 antagonists and 
knockout mice have been found to reduce tolerance and physical dependence during 
chronic opioid administration141. 
ADRB2 is found in the CNS and peripheral tissues responsible for pain signaling, such 
as on primary nociceptive afferents16,142-144, in the dorsal horn144,145, and in the brain 
(hypothalamus). Khasar et al. found that activation of peripheral ADRB2 led to increased 
pain sensitivity and hyperalgesia16,146. Therefore, elucidation of the effects of genetic 
polymorphic variants on receptor expression and functioning in pain-processing pathways 
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could lead to improved choice of therapeutic interventions for pain sufferers. 
 
Background and Significance Summary.  
In the current work, we have begun performing a comprehensive characterization of the 
effect of ADRB2 haplotype on transcription efficiency, mRNA stability, and protein levels. 
Several lines of evidence point toward the role of haplotype in regulating each of these 
components separately and for different receptors, but no comprehensive characterization 
exists to date. We have already examined the effects of ADRB2 promoter on efficiency of 
transcription, and have found evidence for haplotype-specific effects. The ultimate goal of 
this research is to improve the diagnosis and treatment of diseases that are associated with 
ADRB2 by providing a genetic and molecular biological basis for disease etiology and 
modulation.
CHAPTER 2 
RESEARCH DESIGN & METHODS 
 
Single nucleotide polymorphisms (SNPs) can impact the activity of the corresponding 
protein via several mechanisms that are dependent on the position of the SNP along the 
gene locus. SNPs in the putative promoter region of a gene and in the 5'- and 3'-
untranslated regions (UTRs) can modulate transcription efficiency mRNA structural stability, 
and mRNA degradation. Protein translation efficiency can be altered by nucleotide 
substitutions in the coding region of the gene. This can occur without an amino acid change 
of the protein (synonymous) by altering codon recognition and usage, or by altering mRNA 
secondary structure. The functional properties of proteins can be modulated by nucleotide 
substitutions in the coding region that lead to amino acid substitutions of the protein (non-
synonymous). The effect of SNPs on transcription efficiency has already been studied, and 
the results reported in this document. In addition, we propose two additional studies (Future 
Direction & Proposed Experiments, Proposed Studies 1 & 2) that would build on the results 
found in this study, and elucidate the effects of ADRB2 haplotype on mRNA stability and 
ultimately translation. 
 
Rationale.  
The putative promoter region is an area containing a number of transcription factor-
binding site consensus sequences12,56,147,148. Polymorphic variations in this region may lead 
to alteration of transcriptional activation51-54. We performed a haplotype reconstruction to 
identify common haplotypes to be studied in our experiments. There is good evidence that 
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ADRB2 haplotype is a better predictor of polymorphic effects than individual SNPs51,65,66,149. 
We then identified transcription factors whose binding activity can be modified by haplotype-
specific polymorphic variants, which would affect the efficiency of ADRB2 transcription. This 
is an important first step in our analysis since transcription, and specifically regulation of 
transcription initiation marks the beginning of gene expression. 
 
Experimental Procedures. 
Functional SNPs in the 5' intragenic and 5'-UTR are candidates to modify transcription 
efficiency. The internet-based TFSEARCH program was used to search for the ADRB2 
putative promoter, transcription factor binding sites, and other regulatory elements150. This 
program is based on the TRANSFAC database of identified transcription factor consensus 
sequences151. A number of putative transcription factor binding sites have already been 
mapped in the promoter region of ADRB252,54,55,57,152.  
 
Project 1.1. Haplotype Reconstruction.  
We performed a haplotype reconstruction using previously identified ADRB2 common 
SNPs66. Eleven SNPs were chosen based on previous genetic association studies 
identifying their role in cardiovascular and metabolic diseases and were reported in the 
Celera Discovery System (CDS) database65. Genotyping data came from 198 initially pain-
free females and was performed using primers and probes specific to the SNPs of interest—
as done previously by Belfer et al. (2005)65. The haplotype reconstruction was performed 
using the PHASE program153,154. 
 
Project 1.2. Generation of luciferase reporter vector construct, expression vector, and 
transient transfection.  
The role of haplotype on transcriptional activation was assessed using an in vitro 
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luciferase reporter vector system. We cloned the promoter region, from subjects66 (see 
Results) who were homozygous for each of the three major haplotypes, into the luciferase 
reporter vector pGL3-Basic. Luciferase luminescence was used as a surrogate marker for 
transcriptional activation by the ADRB2 promoter. The reporter vector was then transiently 
transfected into an established hepatocellular carcinoma cell line (HepG2) to establish basal 
activation. A number of transcription factors have been cloned into expression vectors and 
were (C/EBP α, C/EBP β, and p65, and CREB) co-transfected with the luciferase reporter 
constructs to assess the role of polymorphic variations in this region on haplotype-specific 
efficiency of transcription. The expression vectors were previously created by cloning full-
length cDNA for the TFs that bind to the identified consensus sequences in the 2.0kb 
promoter region of ADRB2: C/EBPα (NM_004364), C/EBPβ (NM_005194), and p65 
(NM_021975). The constructs used were in the following vectors: C/EBPα (pSV-SPORT 1 
vector), C/EBPβ (pSV-SPORT 1 vector), and p65 subunit of NFκB (pCMV-SPORT-M-p6 
vector). Basal levels and TF-stimulated levels of transcription activation were assessed. 
ADRB2 transcription efficiency was measured indirectly in this system using luciferase 
luminescence as a measure of the cloned promoter’s ability to initiate transcription of the 
luciferase gene. Luciferase luminescence directly corresponds to transcription efficiency of 
the ADRB2 gene. For CREB-dependent transcription an alternative method was used. As 
phosphorylation of CREB is dependent on cAMP generation and PKA activation, we 
exposed cells transfected with the ADRB2 promoter luciferase reporter vector to forskolin, 
an activator of adenylyl cyclase that increases cAMP signaling more directly than using a 
CREB TF construct. For all transfection experiments we cotransfected the β-galactosidase 
expression vector to control for relative levels of transfection efficiency. All data was 
normalized to  
 
Luciferase Reporter Vector 
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Luciferase reporter systems are used routinely as a method of quantifying relative levels 
of transcription efficiency determined by the promoter region. This is done through cloning of 
the putative promoter region upstream to the luciferase gene. TFs present can bind to the 
cloned promoter and alter transcription initiation as if it were in the endogenous state. This 
method is preferable to cloning the entire ADRB2 gene locus (the putative promoter and full-
length cDNA) due to the ability to isolate the putative promoter from the coding region. In 
addition, luciferase luminescence is a convenient way to quantify relative levels of 
transcription readily. The levels of transcription can be compared under different conditions, 
such as through cotransfection with expression vectors containing TF sequences. These 
conditions allow for assessment of the effects of individual TFs on efficiency of transcription. 
The possible problem with this method is that there may be endogenous TFs present in the 
transfected cells that can alter transcription efficiency. To address this potential problem, we 
over-expressed the TFs so that any effects from endogenous TFs were washed out into the 
background. The basal and TF-cotransfected conditions were assessed for changes in 
relative transcription efficiency, so the effects at the basal level from endogenous TFs were 
neither significant nor applicable to this calculation. To address this issue further, we used 
an empty vector control (pCMV-SPORT6) to establish the baseline transcription efficiency in 
the absence of the cloned promoter reporter vectors.  
 
Transient Transfection 
 Transient transfection was used first to introduce the reporter and expression vectors 
into the HepG2 cell line. This cell line was chosen because it highly expressed ADRB2 
endogenously and is expected to have the necessary transcription factors (including and in 
addition to those that were coexpressed) for efficient transcription51. The very reason for 
choosing this cell line, the presence of endogenous TFs, may also introduce a source of 
background by binding to the cloned promoter and altering transcription. This was not found 
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to be a problem as we used appropriate controls, and the transfected promoter and 
cotransfected TF clones were in vast abundance and readily transcribable over the levels 
we would expect for the endogenous TFs. Transient transfection was performed using the 
FuGENE 6® transfection reagent to punch holes in the cell membrane, which allowed the 
vectors to enter and become transiently expressed. This did not involve incorporation of the 
foreign DNA into the genome, which occurs during stable transfection; therefore expression 
of the foreign DNA is not conferred during proliferation. Transient transfection is preferable 
over stable transfection because it allows greater control over baseline transcription which is 
required for comparison of haplotypes. The transfected DNA is controlled by the vector; 
whereas, with stable transfection the transfected DNA is randomly inserted along the 
genome and can lead to altered transcription regulation by surrounding nucleotide context. 
 One potential problem with the transient transfection methodology is the possibility of 
inconsistent and/or low transfection efficiency. This can be due to differences in the ability of 
certain cell lines to incorporate transfected DNA. Low transfection efficiency leaves the 
majority of cells being tested in the non-transfected state, which can lead to a low signal-to-
noise ratio. Another potential problem can occur when the TF expression vectors are 
cotransfected with the luciferase reporter vector. It can be difficult to determine which cells 
incorporated: (a) luciferase reporter only, (b) TF expression vector only, (c) both, or (d) 
neither.  
 
Transfection Efficiency 
Relative transfection efficiency was measured using a β-galactosidase (β-gal) 
expression vector for all of the transient transfection experiments155-157. This vector is 
constructed by inserting a lac operon containing the lacZ sequence into an expression 
vector containing the immediate early CMV (cytomegalovirus) promoter. This promoter is 
activated readily and consistently in mammalian cells and is a good method for determining 
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relative transfection efficiency; it will initiate β-gal (lacZ) transcription only in transfected 
cells. In addition, β-gal can be cotransfected at low concentration without affecting or being 
affected by expression of other endogenous proteins or cotransfected vectors. β-gal is an 
enzyme that normally initiates the breakdown of lactose. In the β-gal assay ortho-
Nitrophenyl-β-galactoside (ONPG) was added to the transfected cells and functioned as a 
substrate for β-gal enzymatic activity. β-gal breaks down ONPG into galactose and ortho-
nitrophenol. The ortho-nitrophenol has a yellow color, which allows measurement of optical 
density. This measurement of β-gal enzymatic activity is used as an indicator of the relative 
levels of transfected β-gal in the cells, and thus the transfection efficiency.  
One potential problem with this method of assessing transfection efficiency is that it 
requires an assumption that β-gal transfection efficiency and expression correlates directly 
with the transfection efficiency of our luciferase reporter and TF expression vectors. The 
assumption is that if the β-gal vector is able to enter the permeabilized cells and undergo 
transcription, then the other vectors should have been able to enter the cells. This is 
generally accepted as true in the research community and when taken in concert with our 
experiments, we assumed that this was an accurate measure of efficiency for the 
transfections we conducted. Our experiments indicated that transfection efficiency was high 
using the HepG2 cell line and that there was not a problem with the vectors being 
incorporated into the permeabilized cells. 
 
Suggested Improvements 
The β-galactosidase method yielded the relative transcription efficiency, which controlled 
for differences among samples caused by inconsistent transfection efficiency and incorrect 
amount of vector added to cells, among others. However, this did not tell us the within-
sample absolute number of cells or proportion of cells successfully transfected. For future 
experiments we would propose to use a second control to determine the absolute levels of 
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transfection (i.e. % cells transfected); we would perform a parallel transfection to the 
experimental conditions, whereby we would transfect the same concentration of an 
expression vector (pCMV-SPORT6) containing a cloned insert of green fluorescent protein 
(GFP). Cells would be visualized by fluorescence microscopy and positively fluorescing cell 
counts compared to non-fluorescing cells to determine absolute transfection efficiency. 
Since the amount of GFP-vector transfected would be the same as the vectors transfected 
for the experimental conditions we would be able to infer the absolute transfection efficiency.
CHAPTER 3 
RESULTS 
 
We have performed a number of analyses and experiments that demonstrate a role for 
ADRB2 haplotype in altering receptor functioning. The goal of these preliminary analyses 
was to identify polymorphisms or groups of polymorphisms (haplotypes) that may alter 
receptor expression. We first performed a haplotype reconstruction to look for associations 
among single nucleotide polymorphisms (SNPs) of the ADRB2 gene locus. We identified 
three haplotypes, which were used in subsequent analyses and experiments. We were able 
to look at the three reconstructed haplotypes for subsequent analyses, rather than individual 
SNPs.  
Once we had identified haplotypes we were able to explore the functional effects of 
haplotype. We first addressed this issue by looking at the effect of promoter haplotype on 
the efficiency of transcription. This was a logical starting place because transcription is the 
first step in the process of gene expression. Specifically we looked at promoter haplotype 
and the consequences on regulatory transcription factor binding consensus sequences. 
These sequences are known to regulate transcription initiation and efficiency; therefore, 
SNPs located within or proximate to these sequences would be expected to alter 
transcription efficiency.  
We were also interested in characterizing the haplotype-specific effects on mRNA 
structural stability. mRNA stability has been shown to alter protein translation by altering the 
ability of the translation initiation machinery from accessing the transcript. In addition, rate of 
mRNA degradation can alter number of mRNA transcripts available for transcription. We 
generated proposed mRNA folding structures to assess the possible role of secondary 
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structure on stability and translation efficiency.  
 
Haplotype reconstruction. 
A haplotype reconstruction was performed using data from a pilot study of healthy 
subjects66. SNPs of interest were identified using the Celera Discovery System and NCBI 
databases. These SNPs were located throughout the promoter and the coding regions of 
the ADRB2 gene locus (Fig. 5). Participants were genotyped for the SNPs, and the 
haplotype reconstruction analysis was performed. The reconstruction yielded three 
haplotypes (H1, H2, and H3) that represented 99% of the study participants. Most of the 
genotyped SNPs were in high linkage disequilibrium with the other genotyped SNPs of the 
gene locus (i.e. not randomly associated, and conferred as a unit rather than as individual 
SNPs). The haplotype reconstruction results were consistent with those previously reported 
for three common haplotypes51,65.  
 
 
 
 
 
 
 
 
 
Figure 5. ADRB2 gene locus, SNP positions, and reconstructed haplotypes. 
Human ADRB2 is a 5.5kb intronless gene on chromosome 5q31-3250. The gene 
locus contains several identified common single nucleotide polymorphism (SNPs). 
Three are located in the coding region and have been associated with alterations in 
ligand binding, functional coupling, and agonist-promoted regulation32,33,51,158. 
 
 
Although the study participants were primarily Caucasians, differences in ADRB2 
haplotype frequency by race have been reported51. These may be accounted for by differing 
evolutionary pressures and advantages conferred by one haplotype over the other by 
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populations yielding from different geographical regions. However, modernization of society 
and movement of peoples may have altered the utility of specific haplotypes; potentially 
leading to reduction, absence, or introduction of new evolutionary pressures. From a clinical 
standpoint, it is important to recognize that individuals of different races may respond 
differently to different therapies due to the different haplotype frequencies present in that 
population.   
 
 
 
 
 
 
Figure 6. ADRB2 promoter transcription factor binding sites. TF consensus 
binding sequences that are known to regulate transcription were identified in the 
promoter region of the ADRB2 gene locus. These were identified within a 2.0kb 
region 5' to the transcription start site. This region of interest was cloned to examine 
transcription efficiency. The TF consensus sequences identified were C/EBPα, 
C/EBPβ, NFκB (p65), and CRE (CREB).  
 
 
Analysis of haplotype-dependent promoter activity. 
We have found that haplotype mediates efficiency of transcription in an in vitro cell 
system. Clones were generated for at least three subjects homozygous for each of the three 
haplotypes. We cloned the 2.0 kb promoter from subject genomic DNA into the pGL3-Basic 
luciferase reporter vector and either cotransfected with TF expression vectors for C/EBPα 
(pSV-SPORT 1 vector), C/EBPβ (pSV-SPORT 1 vector), and p65 subunit of NFκB (pCMV-
SPORT-M-p6 vector) or stimulated directly with forskolin (to activate cAMP signaling). 
Binding sites for these TFs were identified in the promoter region (Fig. 6). In addition, 
putative CREB binding sites (CRE) were identified in the promoter, and forskolin was used 
to activate adenylyl cyclase (AC), which activates CREB signaling (Fig. 6). These 
Transcription 
start site 
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transcription factors correspond to putative transcription factor binding domains identified in 
the 2.0 kb promoter region. The 2.0kb region was selected because of the clustering of TF 
binding consensus sequences that were located along this stretch of the gene locus. In 
addition, putative promoter regions can extend for several kilobases (kb) and affect 
transcription efficiency. The criteria for choosing TFs of interest were: (a) frequency of 
consensus sequences along the promoter, (b) their known role in transcription regulation 
and gene expression, and (c) their proximity to the transcriptional start site. The closer to the 
transcriptional start site at the 3' end of the promoter the greater the expected effect on 
transcription efficiency.  
 
Clones. 
Clones used for the experiments were chosen from among several options based on 
their fidelity to the subjects’ reference DNA sequence. This was done by sequencing the 
genomic DNA of the subjects from which the clones were generated, sequencing the vector 
clones, and comparing the cloned DNA to the reference. We found that the process of 
cloning introduced some unexpected spontaneous mutations not present on the subject’s 
DNA. This type of ‘mistake’ in cloning is not uncommon. We selected two clones for each 
haplotype with the fewest spontaneous mutations to use for all experiments 
 
Cell Lines. 
We used three cell lines for our experiments to examine the possibility of tissue-specific 
effects of transcription regulation by the promoter region. The cell lines express endogenous 
proteins and regulatory factors (i.e. transcription factors) necessary for normal cellular 
functions. These endogenous factors are important to our transfection experiments because 
they facilitate transcription activation by providing the proper environment for the transfected 
cDNA. We picked cell lines that are known to express ADRB2 highly, so that we could 
ensure the proper factors would be present to facilitate transcription of the transfected 
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cDNA. All of the cell lines were of human origin, since we are interested in human ADRB2. 
The full-length cDNA clones that we generated were from human subjects, and would be 
expected to be most efficiently transfected into and transcribed in human cell lines. HepG2 
was chosen because it is a hepatocellular carcinoma derived from the liver, which robustly 
expresses ADRB2. The SH-SY5Y cell line is a neuroblastoma derived from brain. It was 
chosen because of the central role of the CNS controlling the body; particularly due to the 
role of the CNS in modulation of pain sensitivity. The Jurkat cell line (E6-1 clone) is an acute 
T cell leukemia that derives from T lymphocytes. This cell line was chosen due to the role of 
T cells and immune function in the pathophysiology and modulation of asthma. 
 
Results.  
Different levels of basal promoter activity were found to be associated with three ADRB2 
haplotypes, with haplotype 1 coding for the highest level of expression and haplotype 3 
coding for the lowest level of expression in HepG2 cells (Fig. 7). The opposite pattern was 
found for the E6-1 cells (Fig. 9), and haplotype 2 coded for the lowest level of expression in 
the SH-SY5Y cells (Fig. 8). Haplotypes exhibited similar response patterns within each cell 
line, demonstrating haplotype-dependent transcription regulation by C/EBP, p65, and 
forskolin (For) (Fig. 7-9). In all cell lines, C/EBPα and C/EBPβ generally increased 
transcription activity, and p65 generally decreased transcription activity (Fig. 7-9). Contrary 
to our expectation, forskolin did not consistently increase activity of the promoter (Fig. 7-9) 
and in the SH-SY5Y cells it was found to decrease activity of the promoter (Fig. 8).  
 
Interpretation. 
Our preliminary experiments found evidence for basal and TF stimulated haplotype 
effects. The stimulated levels were on average 1.5-2 times higher than the basal 
unstimulated levels (control). The directionality and pattern of effects varied among the cell 
lines, which demonstrates a tissue-specific effect of haplotype on promoter regulation of 
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transcription. This effect size and observed tissue-specificity is consistent with those 
previously seen for polymorphic expression differences51,159-163.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7. ADRB2 promoter activity is regulated by p65, C/EBPα, and C/EBPβ in 
HepG2 cells. Co-expression with the p65 subunit of the NFκB transcription factor 
decreased promoter activity below baseline unstimulated levels (control); whereas 
C/EBPα and C/EBPβ increased promoter activity. Forskolin increased promoter 
activity in haplotype 1. # P < 0.05, * P < 0.01, ** P < 0.001, *** P<0.0001 
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Figure 8. ADRB2 promoter activity is regulated by p65, C/EBPα, C/EBPβ, and 
forskolin (For) in SH-SY5Y cells. Co-transfection with the p65 subunit of NFκB 
decreased promoter activity below baseline unstimulated levels (control); whereas, 
C/EBPα and C/EBPβ increased promoter activity. Forskolin decreased promoter 
activity. # P < 0.05, * P < 0.01, ** P < 0.001, *** P<0.0001 
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Figure 9. ADRB2 promoter activity is regulated by C/EBPα and C/EBPβ in E6-1 
Jurkat cells. Co-transfection with the p65 subunit of NFκB decreased promoter 
activity below baseline unstimulated levels (control) for haplotypes 2 & 3; whereas, 
C/EBPα and C/EBPβ increased promoter activity. Forskolin increased promoter 
activity for haplotypes 2 & 3. # P < 0.05, * P < 0.01, ** P < 0.001, *** P<0.0001 
 
 
 
Problems.  
There were several problems with these experiments that should be addressed in future 
studies. The first improvement would be to use a GFP (green fluorescence protein) 
expression vector as an additional control for transfection efficiency. This would be used in 
addition to the β-gal assay, and would allow quantification of absolute transcription efficiency 
(see Research Design & Methods, Project 1.1).  
Future studies should use the cAMP analog 8-Bromo-cAMP (8-Br-cAMP) instead of 
forskolin. This is due to the mixed results that we observed with the forskolin in our 
preliminary experiments (Fig. 7-9). As an activator of AC, forskolin was expected to initiate 
CREB signaling and increase transcription efficiency. It is possible that the forskolin did not 
efficiently generate cAMP and initiate CREB signaling. This could have been due to several 
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factors in the design of our experiments, such as the method of transfection, properties of 
the vector constructs, or timeline of the experiment. We expect the 8-Br-cAMP to be an 
improved method of activating CREB signaling because it is an analog of cAMP with high 
efficiency of PKA phosphorylation. Use of 8-Br-cAMP should give a more direct measure of 
CREB signaling than just using the CREB expression vector. However, a CREB expression 
vector should also be used to test for CREB activation of ADRB2 transcription. 
Another potential problem with the preliminary experiments was with the construction of 
the cloned promoter expression vectors. The sequence of genomic DNA that was cloned did 
not include the transcription start site. The promoter region 13 base pairs 5' to the 
transcriptional start site was cloned. This is not necessarily a problem because the cis-
regulatory elements controlling transcription efficiency are usually located at least several to 
50 bp upstream to the transcriptional start site. Therefore, we would not expect the 
exclusion of the transcriptional start site and several 5' nucleotides to affect promoter 
regulation significantly. The known CRE element at -50 to -57 bp is included in our construct 
and should not disrupt CREB binding55. In addition, none of the SNPs were located within 
this region, which means exclusion of this region should not have affected haplotype. 
Despite the minimal expected impact of excluding the transcriptional start site, most 
promoter analyses have included the transcriptional start site52,54,55,152. To further complicate 
this issue, NCBI changed the putative transcriptional start site (from version 3—
NM_000024.3 to version 4—NM_000024.4, 10/26/2006) to include an additional 18 bp 
portion of the 5' promoter region (plus an additional 2 bp in the 3' region). This means that 
our constructs do contain this revised putative transcriptional start site, lending validity to the 
constructs that we used, and minimizing the potential impact of not including the older 
reported transcriptional start site. Future experiments should use clones that include the 
version 3 transcriptional start site. The effects should then be compared between the two 
clones to see if there are any differences—we do not believe that any differences would be 
observed. 
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Analysis of haplotype-dependent mRNA secondary structures. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 10. ADRB2 mRNA secondary 
structure. mRNA secondary structure 
stem-loop predictions for each of the 
reconstructed haplotypes: (A) 1, (B) 2, 
and (C) 3.  
 
 
 
 
 
 
 
 
 
 
Analysis of mRNA secondary structure has been conducted using the reconstructed 
haplotypes. We used the Mfold web server164,165 to generate predicted mRNA transcript 
secondary structure folding patterns (Fig. 10). The analyses demonstrated that there are 
significant differences in the predicted folding patterns along the entire mRNA. This is due to 
the fact that there are seven identified SNPs within the ADRB2 mRNA transcript cDNA that 
can significantly alter mRNA secondary structure (Fig. 11), and potentially more that are still 
unidentified. This observation led us to speculate that haplotype effects on mRNA 
A B 
C 
 36 
secondary structure might play an important role in mRNA structural stability. Structural 
stability of mRNA is expected to alter protein translation efficiency and protein levels by 
altering the ability of the translation initiation machinery to access the mRNA121. We propose 
to test this hypothesis in Future Direction & Proposed Experiments, Proposed Projects 1 & 
2. 
 
 
 
ACTGCGAAGCGGCTTCTTCAGAGCACGGGCTGGAACTGGCAGGCACCGCGAGCCCCTAGCACCCG
ACAAGCTGAGTGTGCAGGACGAGTCCCCACCACACCCACACCACAGCCGCTGAATGAGGCTTCCA
GGCGTCCGCTCGCGGCCCGCAGAGCCCCGCCGTGGGTCCGCCCGCTGAGGCGCCCCCAGCCAGTG
CGCTCACCTGCCAGACTGCGCGCCATGGGGCAACCCGGGAACGGCAGCGCCTTCTTGCTGGCACC
CAATGGAAGCCATGCGCCGGACCACGACGTCACGCAGGAAAGGGACGAGGTGTGGGTGGTGGGCA
TGGGCATCGTCATGTCTCTCATCGTCCTGGCCATCGTGTTTGGCAATGTGCTGGTCATCACAGCC
ATTGCCAAGTTCGAGCGTCTGCAGACGGTCACCAACTACTTCATCACTTCACTGGCCTGTGCTGA
TCTGGTCATGGGCCTGGCAGTGGTGCCCTTTGGGGCCGCCCATATTCTTATGAAAATGTGGACTT
TTGGCAACTTCTGGTGCGAGTTTTGGACTTCCATTGATGTGCTGTGCGTCACGGCCAGCATTGAG
ACCCTGTGCGTGATCGCAGTGGATCGCTACTTTGCCATTACTTCACCTTTCAAGTACCAGAGCCT
GCTGACCAAGAATAAGGCCCGGGTGATCATTCTGATGGTGTGGATTGTGTCAGGCCTTACCTCCT
TCTTGCCCATTCAGATGCACTGGTACCGGGCCACCCACCAGGAAGCCATCAACTGCTATGCCAAT
GAGACCTGCTGTGACTTCTTCACGAACCAAGCCTATGCCATTGCCTCTTCCATCGTGTCCTTCTA
CGTTCCCCTGGTGATCATGGTCTTCGTCTACTCCAGGGTCTTTCAGGAGGCCAAAAGGCAGCTCC
AGAAGATTGACAAATCTGAGGGCCGCTTCCATGTCCAGAACCTTAGCCAGGTGGAGCAGGATGGG
CGGACGGGGCATGGACTCCGCAGATCTTCCAAGTTCTGCTTGAAGGAGCACAAAGCCCTCAAGAC
GTTAGGCATCATCATGGGCACTTTCACCCTCTGCTGGCTGCCCTTCTTCATCGTTAACATTGTGC
ATGTGATCCAGGATAACCTCATCCGTAAGGAAGTTTACATCCTCCTAAATTGGATAGGCTATGTC
AATTCTGGTTTCAATCCCCTTATCTACTGCCGGAGCCCAGATTTCAGGATTGCCTTCCAGGAGCT
TCTGTGCCTGCGCAGGTCTTCTTTGAAGGCCTATGGGAATGGCTACTCCAGCAACGGCAACACAG
GGGAGCAGAGTGGATATCACGTGGAACAGGAGAAAGAAAATAAACTGCTGTGTGAAGACCTCCCA
GGCACGGAAGACTTTGTGGGCCATCAAGGTACTGTGCCTAGCGATAACATTGATTCACAAGGGAG
GAATTGTAGTACAAATGACTCACTGCTGTAAAGCAGTTTTTCTACTTTTAAAGACCCCCCCCCCC
CCAACAGAACACTAAACAGACTATTTAACTTGAGGGTAATAAACTTAGAATAAAATTGTAAAAAT
TGTATAGAGATATGCAGAAGGAAGGGCATCCTTCTGCCTTTTTTATTTTTTTAAGCTGTAAAAAG
AGAGAAAACTTATTTGAGTGATTATTTGTTATTTGTACAGTTCAGTTCCTCTTTGCATGGAATTT
GTAAGTTTATGTCTAAAGAGCTTTAGTCCTAGAGGACCTGAGTCTGCTATATTTTCATGACTTTT
CCATGTATCTACCTCACTATTCAAGTATTAGGGGTAATATATTGCTGCTGGTAATTTGTATCTGA
AGGAGATTTTCCTTCCTACACCCTTGGACTTGAGGATTTTGAGTATCTCGGACCTTTCAGCTGTG
AACATGGACTCTTCCCCCACTCCTCTTATTTGCTCACACGGGGTATTTTAGGCAGGGATTTGAGG
AGCAGCTTCAGTTGTTTTCCCGAGCAAAGGTCTAAAGTTTACAGTAAATAAAATGTTTGACCATG 
 
 
Figure 11. ADRB2 mRNA transcript. Haplotype 1 transcript cDNA showing 
identified non-synonymous SNPs (red), synonymous SNPs (green), 
transcriptional start site (NM_000024.3) (yellow), and the translational start site 
(ATG). 
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Conclusion. 
In conclusion, these preliminary analyses have provided promising evidence that 
haplotype significantly alters ADRB2 receptor functioning. We found that the ADRB2 
transcript is regulated by NFκB, C/EBP, and likely cAMP pathways. These data support the 
hypothesis posed by our study that allelic variations in the promoter region will be significant 
predictors of basal and regulated transcription efficiency. There is also evidence of tissue-
specific regulation. Finally, identification of proposed mRNA folding structures for the three 
ADRB2 haplotypes has suggested that secondary structure may be an important factor in 
altered mRNA stability and subsequent translation efficiency—and would be useful to 
examine further (see Future Direction & Proposed Experiments, Proposed Projects 1 & 2). 
CHAPTER 4 
DISCUSSION 
 
Haplotype Reconstruction 
Our haplotype reconstruction confirmed previous findings that there are three major 
ADRB2 haplotypes that account for the majority of genetic variability51,65,66. These 
haplotypes were constructed using known common SNPs that were genotyped from normal 
subjects. These SNPs were located throughout the ADRB2 gene locus: the 5' intergenic, 
putative promoter, 5'UTR, and coding region. The SNPs were in high linkage disequilibrium, 
which demonstrates validity of the haplotype reconstruction in representing common 
haplotypes of individuals. Therefore, additional SNPs that have not been previously 
identified but may result in phenotypic affects, should also be in high linkage disequilibrium, 
and correspond with the three major reconstructed haplotypes. This assumption suggests 
that the reconstructed haplotypes have high genetic and phenotypic predictive value and are 
a useful way to study ADRB2 genotype effects.  
 
Transcription Factors 
In the present work, we found that ADRB2 haplotype affects molecular signaling of 
ADRB2. ADRB2 transcription efficiency was significantly altered by haplotype at basal and 
stimulated levels, and tissue-specific effects were observed. Haplotypes exhibited similar 
response patterns, demonstrating haplotype-independent transcription regulation by 
transcription factors (TF) p65, C/EBP, and CREB. These transcription factors were chosen 
by the high frequency of positive hits within the promoter region using the TFSEARCH 
program to identify putative TF binding sites. These TFs are likely to regulate transcription 
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efficiency of ADRB2.  
The SNPs that were used to determine the three major haplotypes are located 
throughout the cloned promoter region as well as the coding region (Fig. 5). In the promoter 
region, several TF consensus sequences have been identified (Fig. 6). The proximity of cis-
regulatory element consensus sequences for CREB and NFκB to the transcriptional start 
site suggests that they likely are important regulators of transcription efficiency. In addition, 
TATA-box cis-regulatory elements, which regulate transcription initiation and efficiency are 
located near the transcriptional start site. Despite proximity of the consensus sequences to 
the transcriptional start site, none of the genotyped SNPs are located directly within any of 
the sequences. Although this is the case, the SNPs may affect the ability of TFs to access, 
recognize, and bind to the proximate consensus sequences52. In addition, it is likely that we 
would see effects from functional SNPs even if they were not identified or chosen for 
genotyping, due to the high degree of linkage disequilibrium we observed for the genotyped 
SNPs. 
Several putative ADRB2 TF binding site consensus sequences have been identified, 
which include: mRNA cap sites, TATA boxes, C/EBP, Sp150, and a cAMP response element 
(CRE)55. cAMP was found to stimulate transcription of ADRB2 from a cloned promoter upon 
agonist stimulation166. Another study identified a CRE binding site (70 to 37 bp 5' of the 
transcription start site) in the ADRB2 promoter that is responsible for activation of ADRB2 
transcription and confers autoregulatory control on transcription55. This effect occurs as a 
downstream consequence of G-protein-activated cAMP signaling, and is accepted as an 
important method of gene transcription induction for many genes167. cAMP activates PKA, 
which then activates CREB and other transcription factors that bind to gene promoter 
regions and induce transcription. Several TFs have been identified by DNase I footprinting 
and DNA mobility shift assays that bind to sequences in the ADRB2 promoter region: these 
include Sp1, CRE, CP1, AP-2, NF-1, NFκB, and C/EBP. C/EBPα was found to regulate 
ADRB2 mRNA levels and transcription rate negatively in rat liver57. NFκB has been found to 
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increase expression of ADRB2 on human airway epithelial cells indirectly through a PKC 
signaling pathway152, which can occur through Gβγ-induced signaling via a phosphoinositide 
3-kinase (PI3K) pathway. 
 
cAMP (CREB) 
We used forskolin as a surrogate activator of the CREB transcription factor in our 
experiments. Forskolin activates adenylyl cyclase and thus up-regulates cAMP, leading to 
phosphorylation of CREB. CREB then binds to CRE regions on the transfected ADRB2 
promoter construct and regulates transcription of our luciferase gene. We found that in our 
system forskolin significantly decreased transcriptional activity of haplotype 1 in neuronal 
SH-SY5Y cells. This effect was much less pronounced and is in the opposite direction than 
we had expected. We expected forskolin to increase transcription of ADRB2 due to its well-
known role as a transcriptional activator for many genes167. In addition, previous work has 
shown that cAMP specifically stimulates ADRB2 transcription at a CRE transcription factor 
binding site166. In neuronal cells, brain-derived neurotrophic factor (BDNF) has been shown 
to stimulate ADRB2 transcription through the CRE binding site of the ADRB2 promoter168. In 
addition, this stimulation is dependent on the depolarization state of the neuron—BDNF 
activates ADRB2 transcription in polarized neurons (low K+), but represses ADRB2 
transcription and expression in depolarized neurons (high K+). This may explain why we see 
an ‘opposite’ (decreased transcription) effect in our neuronal cells (SH-SY5Y) for forskolin 
than would be expected—the cells may be in the depolarized state. There was a non-
significant trend of decreased ADRB2 transcription in the neuronal cells for the other 
haplotypes, which would agree with the idea that CREB transcription is cell- and 
depolarization state-dependent. Although, there were no significant effects of the forskolin 
(cAMP) for the other cells and haplotypes, there was a trend for increased ADRB2 
transcription in the HepG2 and E6-1 cells. Again, this is in line with the expectation that 
CREB increases ADRB2 transcription, and that there are cell-specific effects on this 
 41 
regulation of transcription. As was mentioned earlier, we did not clone the transcriptional 
start site originally published by NCBI (version 3), which may explain the differences 
observed. The reasons were purely logistical; since the region was particularly G-C rich and 
we had to design the primer more upstream to clone the promoter successfully. It is possible 
that we altered CREB binding to the CRE site at -50 to -57 bp; however we did not omit this 
site. In addition, our clones did include the newer start site reported by NCBI (version 4). 
Moreover, it is possible that our clones affected our results by altering CREB signaling, but it 
does not seem likely given the new NCBI version 4 transcriptional start site, that the CRE 
site is not directly disrupted, and the fact that there are no known SNPs in this region.  
 
p65 
 In HepG2 and SH-SY5Y, p65 (NFκB) decreased transcription activity, and no clear effect 
was seen in the E6-1 Jurkat cells. These results are in contrast to previous findings of 
increased ADRB2 expression by NFκB152. However, these findings were studied in human 
airway epithelial cells (BEAS-2B) and may not be relevant to the liver, neuronal, and T-cell 
cell lines used in the present study. The proteins and accessory factors present in the 
BEAS-2B cells may differ significantly from those of the HepG2 and SH-SY5Y cells, and 
lead to the observed response that is unique to that tissue. We found evidence of tissue-
specific effects of haplotype, and effects of transcription factor with forskolin stimulation. 
Therefore, we cannot be certain that the effects we observed can be generalized to all cell 
types and tissues, and that our findings contradict or refute those previously found with 
NFκB. Another difference between the previous study and our study is that cells were 
stimulated with phorbol 12-myristate 13-acetate (PMA) to induce NFκB production; whereas, 
with our study we cotransfected a p65 expression vector. The advantage of our method was 
that we were able to over-express p65 and ensure that the TF effects were due to mostly 
p65 and no other TFs activated in the cells. The use of the PKC activator, PMA, in the 
previous study led to PKC signaling pathway activation and production of several TFs 
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including NFκB and AP-1. Therefore, this system was much less controlled, and the 
activation of ADRB2 transcription cannot be fully isolated from effects of other TFs and 
effectors. A second consequence of stimulating the cells with PMA is that it could have 
changed the intracellular signaling mechanisms and cellular responses—we did not 
stimulate the cells, but cotransfected with a p65 expression vector. Additional studies 
looking at the effect of PMA stimulation and use of the BEAS-2B cell type in our system 
would clarify the differences observed between the previous study and our study. 
 
C/EBP 
CCAAT-enhancer binding proteins (C/EBPs) are transcription factors that are known to 
be transcriptional activators. There are several subtypes, but the main subtypes associated 
with the ADRB2 promoter are C/EBPα and C/EBPβ. They both bind to the same 
transcription factor-binding site or ‘CCAAT box’ (CCAAT) in the promoter region of the gene 
locus.  
C/EBPα is expressed in a tissue-specific manner in tissues important for energy 
metabolism such as: liver, lung, skeletal muscle, pancreas, small intestine, colon, adipose 
tissue, and peripheral blood mononuclear cells. This suggests a tissue-specific role for 
C/EBPα and confirms that it is located in the same tissues where ADRB2 is known to be 
expressed169. In our study C/EBPα and C/EBPβ were found to increase activity in all cell 
lines tested. This is in line with previous studies of C/EBP in adipose tissue, which activated 
transcription of the serum albumin gene170. However, C/EBPα was found to regulate 
negatively ADRB2 mRNA levels and transcription rate in rat liver57.  
Another factor that may be important to the activation of transcription is the interplay of 
multiple TFs at promoter binding sites. One example of this is with the PEPCK gene, which 
contains a ‘cAMP response unit’ (CRU) comprised of C/EBP, CRE, and AP-1 binding 
sites171,172. Transcription of the gene is regulated through cAMP responsiveness, which is 
modulated by the binding of TFs to all of these sites within the CRU. A CRU or CRU-like 
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domain has not been identified for ADRB2, but it does not mean that this type of interaction 
is not occurring. TFs may interact or require interaction with other TFs in the promoter to 
alter transcription, and the effects may differ based on the tissue, promoter haplotype, and 
conditions. This could be occurring with C/EBPα, which in the PEPCK CRU can substitute 
for CREB and can modulate cAMP responsiveness—domains have been identified in 
C/EBPα that participate in cAMP induction173,174. Again, the fact that we did not include the 
NCBI version 3 transcriptional start site in our clones may have affected c/EBP effect. 
 
Promoter Polymorphisms 
 Previous literature supports the finding that ADRB2 polymorphisms alter efficiency of 
transcription. Effects have been observed for SNPs located in the 5' promoter region of 
ADRB252,53. SNPs in the ADRB2 promoter were found to alter transcription factor binding 
and asthma disease phenotype175. In addition, there was evidence of cell-specific (tissue-
specific) effects between the epithelial and smooth muscle nuclear extracts used. This is in 
line with our finding that transcription efficiency direction and strength of effect varied by cell 
type.  
Scott et al. (1999) expressed several serially truncated ADRB2 promoter constructs in 
COS-7 cells (African green monkey kidney) and found that the ‘wild-type’ construct including 
a 379 segment 5' to the ADRB2 coding region had the highest transcription activity53. 
Constructs including more 5' segments had lower expression, which suggested effects of 
TFs at other binding sites. The -367 SNP within this region was found to alter transcription, 
with the ‘mutant’ construct (-367C) decreasing transcription compared to the ‘wild-type’ (-
367T). Another study found a small effect of the -367 SNP on transcription in peripheral 
blood mononuclear cells (PBMCs)52. The -367 SNP inhibited the binding of an unidentified 
TF complex; however, this SNP was not found to alter down-regulation upon agonist 
stimulation, which suggested a role for altering basal levels of transcription52. This result is in 
line with our findings that ADRB2 promoter haplotype leads to different basal levels of 
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transcription in the cell lines used. A third study found only minor effects in PBMCs, but with 
a trend toward increased cAMP response for the C allele176. This study was conducted in 
PBMCs, which may not represent the effects we observed in our cell types. Ultimately, the 
previous literature supports a link between ADRB2 promoter SNPs and transcription 
efficiency.   
 
Haplotype 
The present study was conducted using reconstructed ADRB2 haplotypes. Haplotypes 
were used instead of SNPs, due to findings in the previous literature that ADRB2 promoter 
haplotype is a better predictor of phenotype than individual SNPs51,54. Although, one study 
did not find any functional effects of ADRB2 promoter SNPS or haplotype176. We found 
significant effects of haplotype in our study 
Drysdale et al. (2000) found haplotype effects in their clinical study of in vivo 
responsiveness to ADRB2 agonist: Asthmatics were treated with an ADRB2-specific agonist 
and responsiveness was tested as change in forced expiratory volume in 1 second (FEV1). 
Subjects homozygous for their haplotype 2 (our haplotype 1) had a greater change in FEV1 
(15%) upon agonist treatment, than homozygotes for their haplotype 4 (our haplotype 
2)(8.5%). This pattern corresponded best with our HepG2 (liver) data, which showed a trend 
for highest transcription in haplotype 1, lower in 2, and lowest in 3. The reverse trend was 
observed with the E6-1 (T cells). These measures of haplotype effect are very different; 
therefore, we cannot draw direct comparisons between them. This study also found a 
difference in ADRB2 in vitro protein and mRNA levels in HEK293 (human kidney). Their 
haplotype 2 (our H1) surface protein level was approximately 1.5 greater than haplotype 4 
(our H2) and mRNA level was two times greater. This effect is in line with the trend for E6-1 
and SH-SY5Y. It is difficult to draw any direct conclusions since: a) the cell lines used are 
not comparable, b) the in vivo and in vitro effects are not consistent, and c) the methods 
used to express and measure mRNA in our experiments were different from this study. 
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However, we can draw the conclusion that ADRB2 haplotypes leads to differences in mRNA 
expression and is supported by previous findings. The authors expanded on this further and 
concluded that individual SNPs had poor phenotypic predictive power in comparison to 
haplotype.  
 Another study by Johnatty et al. (2002) found that promoter haplotype led to differences 
in transcription levels that could not be accounted for by individual SNP54. However, this 
study looked at theoretical haplotypes of four promoter SNPs (-468 C→G, -367 T→C, -47 
T→C, and -20 T→C), which do not necessarily represent common haplotypes present in the 
population. Differences were only found in theoretical, non-common promoter haplotypes. 
The haplotypes that corresponded to our reconstructed haplotypes showed no difference in 
ADRB2 transcription level. This is in contrast to our findings and those of Drysdale et al. 
2000 that three common haplotypes show specific transcription effects. This could be due to 
the fact that their haplotypes did not distinguish between our H2 and H3, which could have 
led to a washing out of an observed effect—they did not include SNPs from the coding 
region and further upstream in the promoter. However, this study is still important as a 
demonstration of how haplotype is a better genetic analysis tool than individual SNPs.  
 This last study by Johnatty et al. (2002) highlights the importance of picking a variety of 
known SNPs along a gene locus when performing an association analysis54. For our 
haplotype reconstruction we used this principle, which corresponded with the reconstruction 
of Drysdale et al. 2000; we also mimicked the protocol used by Belfer et al. 200565. Belfer’s 
group highlighted the importance of this concept and added that good selection of SNP 
markers leads to better predictive power of the haplotype for yet unidentified SNPs that 
might be functional. This statement is bolstered by the fact that most of the SNPs used in 
the haplotype reconstruction were in high linkage disequilibrium (non-random association of 
alleles at two or more loci); therefore, we would expect other unidentified SNPs also to be in 
linkage disequilibrium with known SNPs. Moreover, haplotype reconstruction allows 
characterization of the genotype and accounts for effects of most SNPs, even those that are 
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yet to be identified. 
 
mRNA Secondary Structure 
 mRNA secondary structure was predicted for each of the haplotypes. The theoretical 
stem-loop structures vary considerably by haplotype, and show similarity in only one 
domain; the bottom left of each panel in Figure 8. These differences suggest a plausible 
effect of haplotype on secondary mRNA structure and thus biological activity of ADRB2 on 
the level of efficiency of translation 177-182 or rate of mRNA degradation183-190. This effect has 
not been studied for ADRB2, but has been studied by our lab for the enzyme COMT121. We 
believe that future studies should be carried out that will test a biological significance of this 
observed altered secondary structure, as the effects may be expected to be dramatic due to 
the great difference in secondary structure among haplotypes.  
 
Conclusion 
The ADRB2 transcription is regulated by NFκB, C/EBP, and likely cAMP pathways (by 
CREB), although the direction of effect was not the same as that previously reported. We 
also found that haplotype altered the efficiency of transcription in response to transcription 
factor binding. This could be due to the presence of SNPs near or within putative promoter 
TF cis-regulatory binding domains. The SNPs comprising each haplotype could alter the 
ability of TFs to recruit the transcription initiation machinery to bind and transcribe mRNA, 
which would lead to decreased mRNA levels. Understanding haplotype differences in 
transcription efficiency is an important component of ADRB2 characterization  
 
Future Direction 
 The findings that ADRB2 haplotype alters efficiency of transcription lends support to 
further study of the effects of haplotype on receptor functioning. The proposed future 
experiments (Future Direction & Proposed Experiments section) will elucidate the effect of 
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haplotype on ADRB2 mRNA and protein levels. This might occur following transcription 
through alteration of mRNA stem-loop structure and folding stability (without altering 
absolute levels of mRNA). We already have evidence from the predicted mRNA stem-loop 
plots, which vary considerably by haplotype, that there is likely to be an effect of secondary 
structure. Decreases in mRNA independent of promoter effects could occur due to 
haplotype effects on mRNA degradation rate. Decreased mRNA levels can directly lead to 
decreased protein levels, simply due to fewer transcripts being available to participate in 
translation. However, haplotype effects on mRNA folding that do not lead to changes in 
mRNA level, might alter the ability of translation machinery to access the transcript and lead 
to decreased protein levels. Elucidating haplotype effects will lead to better clinical diagnosis 
and treatment of disorders caused by these haplotype-specific alterations. 
CHAPTER 5 
FUTURE DIRECTION & PROPOSED EXPERIMENTS 
 
The experiments we conducted give a good basis for the prediction that other haplotype 
effects would be observed for ADRB2. In order to fully characterize the effect of haplotype 
on ADRB2 functioning, there are two main lines of research that would need to be 
conducted. These are: a) the role of haplotype on mRNA structural stability, and b) the role 
of haplotype on protein level. At a basic science level, these experiments would further 
contribute to the understanding of how haplotype affects receptor functioning, but at a 
clinical level they would help elucidate the role of haplotype on clinical phenotype and 
treatment. 
 
Proposed Study 1. To examine the effects of haplotype on mRNA structural stability. 
 
Rationale. 
The effects of polymorphic variants in exons on mRNA sequence recognition motifs are 
well-characterized. Specifically, mRNA stability has been shown to be modulated by 
regulatory sequence motifs in the 3' untranslated region as well as along the transcripts1-13. 
The 3' UTR has been shown to regulate agonist-mediated mRNA stability3,14,15. Haplotype-
specific effects have been shown to alter mRNA stability and protein translation 
efficiency3,16-26. SNPs have been identified in regulatory motifs on the ADRB2 gene locus 
that alter mRNA stability15,27. Polymorphic variants can also affect mRNA secondary 
structure19,21,22, and alter mRNA stability19-21. Recent work by our group has demonstrated 
that mRNA secondary structure can directly affect protein translation efficiency and exhibits 
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haplotype-specific effects21. Our preliminary data have identified alternative mRNA 
secondary structures coded by three major ADRB2 haplotypes (see Results section and Fig. 
10). Therefore, we propose that haplotype may affect mRNA stability through alterations in 
sequence motifs (degradation stability) and/or through alteration of secondary structure 
(structural stability).  
 
Experimental Procedures.  
 
Proposed Project 1.1. Generation of full-length cDNA clones. 
We propose to clone full-length ADRB2 cDNA (NCBI NM_000004) from subjects28 
homozygous for each of the three major haplotypes, into the expression vector pcDNA3. 
Constructs would then be transiently transfected into an established hepatocellular 
carcinoma cell line (HepG2) and a neuroblastoma cell line (BE(2)-C).  
 
Proposed Project 1.2. Measuring mRNA level and stability. 
Basal mRNA levels would be determined for each of the full-length cDNA clones 
transiently transfected into the cell line. Total RNA would be isolated from cell extracts using 
Trizol reagent and mRNA levels corresponding to ADRB2 would be measured using real-
time PCR. Reverse-transcriptase PCR would be performed on the isolated total mRNA. 
ADRB2 cDNA would be amplified using the DyNAmo-SYBRGreen qPCR kit, and quantified 
using the Eppendorf® Mastercycler® ep realplex real-time PCR machine. mRNA degradation 
stability would be assessed through addition of the non-specific transcription inhibitor 
actinomycin-D. This would be done using a time-course to determine mRNA degradation 
rate.  
 
Proposed Project 1.3. Predicted haplotype-specific mRNA secondary structure. 
Preliminary predicted folding patterns of the full-length ADRB2 cDNA transcripts have 
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already been generated for the three reconstructed haplotypes using the Mfold web 
server23,29 (see Results section, Fig. 10). Further analysis would be performed using a newer 
algorithm (Afold, ftp://ftp.ncbi.nlm.nih.gov/pub/ogurtsov/) for calculating Gibbs minimum free 
energy (ΔG) and optimal folding24, which is based on previously reported methods23. The 
new algorithm would assess primarily stacking and loop length to determine the optimal 
multi-branch loop-free (MLF) structure.  
 
Proposed Project 1.4. Site-directed mutagenesis to alter mRNA secondary structure. 
If differential effects at the level of mRNA stability (Proposed Project 1.2) or protein 
translation (see Proposed Project 2.1) were to be observed, site-directed mutagenesis 
would then be performed that would be predicted to alter mRNA secondary structure, mRNA 
sequence recognition motifs, or protein folding. We would start by performing single 
nucleotide mutagenesis on nucleotides at the base of stable stem-loop structures that might 
be important for secondary structure stability, this is analogous to the approach used for the 
COMT gene21. We would then look at adjacent nucleotides that might also disrupt stable 
structures. This would be done using the predicted folding patterns of the Mfold and Afold 
algorithms23,24,29. As necessary we would perform double mutagenesis and mutagenesis that 
‘rescues’ an unstable region. Mutagenized clones would be transiently transfected, and 
mRNA stability measured. A time course would be performed following addition of 
actinomycin-D, to determine mRNA degradation rate. 
 
Proposed Project 1.5. mRNA sequence motifs. 
If were not to find haplotype effects of mRNA secondary structure on stability, we would 
explore the role of mRNA sequence motifs in regulating mRNA stability. We would clone the 
3' UTR for each of the haplotypes and insert it into the 3' region of the pGL3-Basic luciferase 
reporter vector27. We would then transfect the reporter vector into the cell line. We would 
measure both basal luciferase mRNA level and luciferase protein expression. We would 
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then measure mRNA degradation by adding the transcriptional inhibitor actinomycin-D, and 
performing a time course measurement (similar to Proposed Project 1.2). 
 
Interpretation and Anticipated Problems. 
 
Proposed Project 1.1. Generation of full-length cDNA clones. 
Full-length 2.0kb ADRB2 cDNA would be used to express mRNA in the transfected cells. 
Full-length cDNA sequences are normally constructed from the gene transcripts and 
encompass the entire coding region of the gene, the transcriptional start site, and 3' 
untranslated region. Since the ADRB2 gene is intronless, we would be able to amplify DNA 
fragments, corresponding to full-length cDNA, directly from genomic DNA of homozygous 
subjects. This would bypass use of cDNA clones from the I.M.A.G.E. Consortium Library 
(http://image.llnl.gov). The full-length ADRB2 cDNA would be expected to be expressed 
readily in the HepG2 cell line. This cell line derives from the liver, which highly expresses 
endogenous ADRB2. In addition, for our current study we have demonstrated high 
transfection efficiency and transcription efficiency of the cloned promoter luciferase reporter 
vector constructs. We would plan to use the BE(2)-C cell line to see if there are any tissue 
differences in expression. 
 Using full-length cDNA clones has a considerable advantage over measuring 
endogenous ADRB2 mRNA levels. We would be able to control the haplotype of the cDNA, 
which would allow evaluation of haplotype-specific effects, comparing mRNA corresponding 
to three haplotypes side-by-side in controlled standardized conditions. The endogenous 
transcriptional events would lead to some background, but an empty vector control and β-
gal would both be used to normalize the samples to background levels.  
 One argument against use of in vitro transfection of full-length cDNA clones is that they 
may not be physiologically relevant because they do not evaluate endogenous 
transcriptional and translational events. There is validity to this argument; however, it is 
 52 
difficult to study transcription in an endogenous system due to the many confounding 
variables. These confounding variables include endogenously expressed TFs, upstream and 
downstream regulators, feedback mechanisms, etc. These all can potentially affect 
transcription and mRNA levels and can contribute to confounding effects that are not easy to 
correct for or normalize. Therefore, the system of cloning full-length cDNA would allow for 
analysis of transcription and mRNA levels in relative isolation; yet still within a cell system 
that is known to express ADRB2 and would be expected to transcribe the cDNA easily. 
 
Proposed Project 1.2. Measuring mRNA level and stability. 
Basal levels of mRNA would be measured using real-time PCR. This method is well 
characterized and a well-validated method for quantification of relative levels of mRNA. 
mRNA degradation rates would tell us how stable the mRNA is. We would expect to see 
haplotype effects in the degradation stability of mRNA due to the role of sequence motifs as 
well as alteration of secondary structure by individual or groups of SNPs in the three 
haplotypes. Moreover, the initial basal mRNA levels (i.e. transcription efficiency, see 
Results) might be unaffected by haplotype, but may be more prone to degrade (less stable) 
over time and lead to functional consequences on translation. If no differences were to be 
seen for mRNA levels, then we would look at the protein levels to determine if the effects 
were occurring at the level of translation (see Proposed Project 2). 
 
Proposed Project 1.3. Predicted haplotype-specific mRNA secondary structure. 
The Mfold mRNA folding algorithm is an accepted method for predicting mRNA 
secondary structure. The improved Afold algorithm would be used to estimate folding in 
conjunction with the Mfold program for all experiments. We have recently shown that the 
ADRB2 haplotypes differ significantly in their predicted mRNA secondary structure (see Fig. 
10) and that haplotype differences in secondary structure of another gene can affect mRNA 
 53 
and protein level21. One problem with analysis of the predicted folding patterns is that the 
structures differ so significantly and only have one domain in common. This could make 
analysis of sites responsible for secondary structure stability difficult, as domains cannot be 
easily compared among local stem-loop structures for each haplotype.  
 
Proposed Project 1.4. Site-directed mutagenesis to alter mRNA secondary structure. 
If we were to observe a haplotype effect on mRNA stability, first we would examine the 
role of secondary structure by altering stable stem-loop structures. We would perform site-
directed mutagenesis at the base of stable structures to disrupt the secondary structure. By 
altering local structures specific to different haplotypes we would be able to assess whether 
or not haplotype alters structural stability through altering secondary structure. We would 
then be able to attribute the effects of these local structures to the three reconstructed 
haplotypes. We would identify regions that may be important to secondary structure and 
mRNA structural stability by looking at the predicted folding patterns generated by the Mfold 
and Afold algorithms23,24,29 and nucleotides located at the bases of the steam-loop structures 
would be chosen for mutagenesis21. 
 
Proposed Project 1.5. mRNA sequence motifs. 
We would use the luciferase reporter system as a surrogate for regulation of protein 
expression (i.e. luciferase protein) by the 3' UTR (the inserted sequence from the three 
ADRB2 haplotypes27). Motifs responsible for mRNA degradation and stabilization are usually 
located in the 3' UTR of the mRNA and have been found to alter stability of ADRB2 
mRNA3,14,15. Therefore, we would expect to observe regulation of mRNA stability by the 
inserted 3' UTR region. The measure of mRNA level would tell us whether or not sequence 
motifs regulate mRNA stability and are haplotype-dependent. The second aspect of this 
project, to look at the protein level through luciferase expression, would measure the effect 
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of sequence motif haplotype on regulation of translation. Since altered mRNA stability leads 
to alterations in protein translation, we would expect to see altered protein translation and 
levels if sequence motifs were to alter mRNA structural stability.  
 
Proposed Study 2. To examine the effects of haplotype on protein level.  
 
Rationale. 
Decreased mRNA stability leads to decreases in mRNA levels and consequently in the 
amount of translated protein16,17,19,22,30,31. Moreover, tight folding of the mRNA, which 
prevents access to the mRNA by the translation initiation machinery32 and RNA-binding 
proteins (RBPs)31 may decrease translation efficiency. RBPs act by regulating translation 
upon binding to cis-regulatory elements in the 5' and 3' UTRs of mRNA31,33. Three non-
synonymous SNPs (those leading to amino acid changes) are located within the coding 
region of ADRB2: two in the amino terminus at codons Arg16Gly (G/A, rs1042713) and 
Gln27Glu,(C/G, rs1042714), and one in the fourth transmembrane spanning domain at codon 
Thr164Ile (G/A, rs1042717). The Gly16 receptor undergoes enhanced agonist-promoted 
down-regulation in receptor number in comparison to the Arg16 receptor. In contrast, the 
Glu27 receptor undergoes very little agonist-promoted down-regulation compared to the Gln27 
receptor. These variants are common in human populations and have been extensively 
studied (for review see Small et al. 2003)34. The Ile164 receptor displays decreased Gs 
coupling34,35. Polymorphic variants causing non-synonymous amino acid changes, such as 
these, can affect protein stability by leading to changes in protein folding caused by altered 
hydrogen bonding and hydrophobic interactions36,37. Polymorphic variants leading to 
synonymous amino acid changes (nucleotide changes that do not result in an amino acid 
change) in exons have been found to affect efficiency of translation by altering mRNA 
secondary structure and protein expression levels21. 
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Experimental Procedures 
 
Proposed Project 2.1. Protein level. 
Protein levels would be assessed by Western blotting. HepG2 and BE(2)-C cells would 
be transiently transfected with the full-length ADRB2 cDNA clones in Proposed Projects 1.1 
and 1.2, and a subset of the cells would be set aside for measuring protein level. This would 
be done for the basal mRNA levels and for the levels following addition of the transcription 
inhibitor. We would also measure protein levels for the mutagenized clones (Proposed 
Project 1.4) to determine the effects of altered mRNA secondary structure on protein level. 
 Cell lysates would be purified and normalized for protein content using the bicinchoninic 
acid (BCA) assay38. Lysates would then be run on a 10% Tris-Glycine gel and transferred to 
a polyvinylidene difluoride (PVDF membrane). Blots would be blocked and incubated with 
ADRB2 polyclonal primary antibody (Santa Cruz, Cat# sc-569), a polyclonal secondary 
antibody, and then a chemiluminescent agent for visualization by densitometry. To control 
for amount of protein loaded in the wells, the blots would be stripped and incubated with a β-
actin polyclonal primary antibody. Bands would then be analyzed for relative levels of 
ADRB2 and normalized against β-actin levels. 
 
Proposed Project 2.2. Receptor density. 
Cell-surface expression of ADRB2 would be determined by radioligand binding assay. 
This would allow for quantification of receptor number on cells transfected with each 
haplotype. We would determine total binding by exposing cells to varying concentrations 
(10-150pM) of the radioligand adrenergic antagonist (-)-[125I]-iodocyanopindolol (ICYP) for 
90 minutes at 37°C39,40. The reaction would be halted with ice cold Tris-HCl/NaCl buffer, 
filtered rapidly, and a γ count made. Nonspecific binding would be determined by adding a 
saturating concentration (10µM) of unlabeled +(-)propranolol to cells and adding 100pM 
ICYP. Specific binding would be determined by subtracting nonspecific binding from total 
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binding. Maximal specific binding (Bmax) and binding affinity (Kd) would be determined using 
nonlinear regression analysis software. A competition binding assay would be performed to 
determine specificity (Ki) of antagonists to the three β-adrenergic subtypes in the transfected 
cells: ADRB1 (metoprolol), ADRB2 (ICI 118, 551), and ADRB3 (SR 59230A). Cells would be 
treated with 100pM ICYP and unlabeled antagonists (100pM-100μM)39. Specificity would 
then be used to infer which receptor subtype is likely the most abundant. 
 
Proposed Project 2.3. Efficiency of translation and site-directed mutagenesis. 
Translation efficiency would be determined by measuring basal protein levels and 
comparing them to levels for the mutagenized clones generated in Proposed Project 1.4. 
We would expect increased stability to yield decreased protein levels. We would also 
perform site-directed mutagenesis on the full-length cDNA clones in regions thought to 
regulate translation initiation and efficiency, primarily the SNPs immediately 5' to translation 
initiation site. We would then evaluate the effect on mRNA and protein level. 
 
Proposed Project 2.4. Codon usage. 
If no effect were seen for the previous projects, we would then perform site site-directed 
mutagenesis on the full-length ADRB2 cDNA clones within the coding region at SNPs that 
code for synonymous amino acid changes. We would do this only for the highest protein-
expressing haplotype. We would measure mRNA and protein levels to determine effect of 
codon usage. Finally, we would measure cAMP levels to determine possible functional 
effects of codon usage.  
 
Interpretation and Anticipated Problems. 
 
Proposed Project 2.1. Protein level. 
This method of protein quantification is well established and has already been used for a 
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number of years by members of our research group; we have successfully quantified 
ADRB2 using this method. The major drawback inherent in this method is the dependence 
on the use of an ADRB2 primary antibody. This can introduce background as there might be 
non-specific binding to other proteins. However, preliminary experiments using this antibody 
have demonstrated low non-specific binding. β-actin would be used as a control for loaded 
protein amount, and can be used for normalization of the bands. If differences were to be 
seen in the amount of protein, we would compare the mRNA levels to determine if the 
haplotype effects were due to translation efficiency (Proposed Project 2.3) alone or if they 
were the result of altered mRNA stability. 
 
Proposed Project 2.2. Receptor density. 
Receptor density measured by a radioligand binding assay is a more precise and 
quantitative measure of protein level than Western Blot. We could measure the precise 
number of cell-surface expressed receptors on cells transfected with each of the three 
ADRB2 haplotypes; whereas, the Western is not an absolute measure, but a relative protein 
measure. Westerns are limited by the relatively poor optical resolution of their output, which 
can lead to washed out differences between samples (bands). This makes Westerns a poor 
choice for smaller differences in protein level (such as less than 2-fold differences in 
expression); although, they can be a good choice for larger differences. In addition, 
antibodies used for Westerns can lead to non-specific binding or poor, which can wash out 
or mask differences among samples. We propose to perform both Western blots and 
radioligand binding assays to confirm differences in protein levels, since both methods are 
well-established and used regularly. 
 Bmax is a measure of total receptor number and is the functional measure for the 
radioligand binding assay. We would compare calculated Bmax among samples to determine 
differences in protein level. Since ICYP detects all β-adrenergic subtypes, we would use Ki 
is an indirect measure of which receptor type(s) are in the highest abundance (i.e. if the 
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measured Ki were to be similar to the known Ki of ICI 118, 551 for ADRB2 and dissimilar to 
the Ki of metoprolol for ADRB1 and SR 59230A for ADRB3, then we would be able to say 
that ICYP is likely measuring ADRB2 receptors). Since we would be over-expressing 
ADRB2 in the cells by transfection we would expect most of the surface-bound β-adrenergic 
receptors to be ADRB2; therefore, ICYP would be a good measure of ADRB2. 
 
Proposed Project 2.3. Efficiency of translation and site-directed mutagenesis. 
One way that translation efficiency can be affected by haplotype is through alterations in 
mRNA secondary structure. As shown previously, more stable mRNA secondary structures 
are expected to lead to decreased protein translation and levels16-18,21. This is due to the 
inability of the translation machinery to access the mRNA transcript to facilitate translation. 
This decreases translation initiation, which leads to decreased protein levels. Another way 
that translation efficiency can be affected by haplotype is through the 5' and 3' untranslated 
cis-regulatory domains. These domains are specific for regulatory RNA-binding proteins 
(RBPs) that can alter efficiency of translation (these ‘translation factors’ are conceptually 
similar in function to the action of transcription factors). SNPs located within or near these 
domains may alter the ability of RNA-binding proteins to bind and regulate translation 
initiation. Two SNPs of interest (rs1801704 and rs34399297) are primary targets for 
potential effect on translation efficiency due to their 20bp and 23bp upstream proximity to 
the first ATG of ADRB2. However, other SNPs along the ADRB2 gene locus (particularly in 
the 3' UTR) may affect translation efficiency. SNPs in the 3' UTR could affect translation 
through association of the mRNA 3' tail with the 5' region, forming the characteristic loop or 
circular structure to the mRNA during translation33,41,42. 
 
Proposed Project 2.4. Codon usage. 
The codon usage bias is a phenomenon by which a preference is shown by tRNA during 
translation for a particular codon(s) that code(s) for the same amino acid. This preference 
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can affect translation by increasing the rate and fidelity of translation by tRNA. Synonymous 
amino acid changes caused by SNPs that otherwise would not be expected to lead to 
protein translation alterations can lead to changes in translation efficiency due to codon 
usage16,19,25,43. Codon usage would be evaluated only if mRNA stability and mRNA 
sequence motifs were not found to regulate translation. This would be the case if mRNA 
stability and levels were found to be normal and unaffected by haplotype, but protein levels 
were affected by haplotype. This would be measured by performing site-directed 
mutagenesis on the full-length ADRB2 cDNA clones within the coding region at SNPs that 
code for synonymous amino acid changes. We would do this for the highest protein-
expressing haplotype. If protein levels were to be lower in the mutant then, we would 
conclude that codon usage caused the decreased protein level. We would not expect codon 
usage to contribute significantly to haplotype effects on protein levels, since our preliminary 
analysis (Fig. 10) found significant haplotype differences in the predicted mRNA secondary 
structures. 
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